1Pootoolal J, Neu J, Wright GD. Glycopeptide antibiotic resistance [ J ]. Annual Reviews of Pharmacology and Toxicology, 2002,42:381-408.
2Livermore DM. Antibiotic resistance in Staphylococci [J]. Int J Antimicrob Agents,2000,16 (Suppl 1) :3-10.
3Micek ST. Alternatives to Vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections [ J ]. Clinical infectious diseases,2007,45 ( Suppl 3):184-190.
4Krzysatof S, Alexander T. Inhibition of cell wall and autalysis by vancomycin in a highly vancomycin resistant mutant of staphylomecus aureus[J]. J Bacteriol, 1997,179(8):2557-2566.
5Goldstein BP, Draghi DC, Sheehan DJ, et al. Bactericidal Activity and Resistance Development Profiling of Dalbavancin[J]. Antimicrobial Agents and Chemotherapy, 2007,51(4):1150-1154.
6Allen NE ,Nicas TI. Mechanism of action of oritavancin and related glycoprptide antibiotics[J]. FEMS Microbiology Reviews, 2003,26:511-532.
7Mercier RC, Hrebiekova L. Oritavanein:a new avenue for resistant Gram-positive bacteria[J]. Expert Rev Anti Infect Ther,2005,3(3) :325-332.
8Walker S, Chen L, Hu Y, et al. Chemistry and Biology of Ramoplanin: A Lipoglyeodepsipeptide with Potent Antibiotic Activity[J]. Chemical Reviews,2005,105:449-475.
